GH Research PLC is rated a Buy with $280.7M in cash, supporting lead candidate GH001 for Treatment-Resistant Depression. Read more on GHRS stock here.

Q4 2025 Earnings Call March 10, 2026 9:00 AM EDTCompany ParticipantsAnthony Pike - Chief Financial OfficerBrent Bruun ...

Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced fourth quarter and fiscal year 2025 financial results for the twelve months ended December 31, 2025. Nutex Health is ...

This shareholder letter follows the completion of our fourth quarter and fiscal year ended December 31, 2025.

To put that into perspective with some numbers, for someone with a balance of $7,000 at the current rate of 23.77%, making monthly payments of $250 will require over three years to pay off their ...

CEO Schapper said, “We believe that these focus areas and the related transformation objectives will drive desired strategic ...

Whether you’re already saving for a college education or looking to get started, the provides an opportunity to set aside ...

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 ...

Myers Industries, Inc. (NYSE:MYE) Q4 2025 Earnings Call Transcript March 5, 2026 Myers Industries, Inc. beats earnings ...

Singapore. Singapore has four national programs to build assets for children: the Baby Bonus Child Development Account, the ...

Conference call today at 8:30 a.m. ET ORLANDO, FLORIDA / ACCESS Newswire / March 9, 2026 / Unusual Machines (NYSE American:UMAC) ("Unusual Machines" or the "Company"), a leading provider of NDAA-compl ...